Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(21/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(21/week)
News
United States
(584/week)
Manufacturing
(403/week)
Energy
(324/week)
Technology
(409/week)
Other Manufacturing
(343/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Calcitonin gene-related peptide receptor antagonist
May 18, 2020
Biohaven Showcases Clinical and Pharmacoeconomic Data for NURTEC(TM) ODT (rimegepant) with 25 Presentations on the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform
Apr 09, 2020
Biohaven Receives FDA May Proceed Letter to Begin Phase 2 Trial of Intranasal Vazegepant to Treat Lung Inflammation After COVID-19 Infection
Feb 10, 2020
Biohaven's Rimegepant Named To Cortellis 2020 Potential Blockbuster "Drugs to Watch" List
Dec 17, 2019
Biohaven Achieves Positive Topline Results in Pivotal Phase 2/3 Study of Vazegepant, The First and Only Intranasal CGRP Receptor Antagonist in Clinical Development for the Acute Treatment of Migraine
Nov 01, 2019
Biohaven Pharmaceuticals Reports Third Quarter 2019 Financial Results And Recent Business Developments
Jul 11, 2019
Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting Demonstrating Efficacy in Multiple Patient Types and Long-term Safety
Jul 10, 2019
Biohaven's Rimegepant Positive Phase 3 Trial For Acute Treatment Of Migraine Published In The New England Journal of Medicine
Jul 09, 2019
Allergan Continues to Demonstrate Leadership in Migraine with 29 Presentations at the 2019 American Headache Society Annual Meeting
Jun 24, 2019
Biohaven To Present 16 Abstracts At 2019 American Headache Society (AHS) Annual Scientific Meeting Highlighting New Data With Rimegepant, Oral CGRP Receptor Antagonist
Oct 22, 2018
Biohaven Receives Authorization to Proceed from FDA and Doses First Subject with BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist
Sep 12, 2018
Biohaven Announces Submission of IND for BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist for the Treatment of Migraine
Sep 06, 2018
Biohaven Presents at Migraine Trust International Symposium and Highlights Positive Results from Study 301 and Study 302 of Rimegepant, an Oral CGRP Receptor Antagonist, in the Acute Treatment of Migraine
Aug 14, 2018
Biohaven Pharmaceuticals Reports Second Quarter 2018 Financial And Recent Business Results
Jun 05, 2018
Biohaven to Present Key and Expanded Data from Phase 3 Clinical Trials of Rimegepant, its Oral CGRP Receptor Antagonist, During Four Late-Breaking Sessions at American Headache Society (AHS) Annual Scientific Meeting 2018
May 15, 2018
Biohaven Pharmaceuticals Reports First Quarter 2018 Financial and Recent Business Results
Apr 19, 2018
Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los Angeles
Mar 12, 2018
Biohaven Restructures License Agreement With Bristol-Myers Squibb To Reduce Royalties Payable On Its Migraine Product Candidates; Transaction Financed Through Private Placement With Leading Institutional Investors
Jun 16, 2017
Biohaven Pharmaceuticals Reports First Quarter 2017 Financial and Business Results
Latest News
May 12, 2024
Three Hillsdale College Graduating Seniors Commissioned by U.S. Marine Corps
May 12, 2024
Boeing's problems rattle US aviation regulator as well
May 12, 2024
Concern about Russia dominates as Lithuanians vote
May 12, 2024
Ørsted and Shipbuilder Edison Chouest Christen First-Ever American-Built, Offshore Wind Service Operations...
May 11, 2024
Pembina Pipeline Corporation Reports Voting Results from 2024 Annual Meeting of Shareholders
May 11, 2024
Terran Orbital Schedules Conference Call to Discuss First Quarter 2024 Financial Results
May 11, 2024
Fonon Corporation Highlights Applications for Its Laser Cutting Technology in the Mining Industry
May 11, 2024
Sky Harbour to Report 2024 Q1 Results and Host Webcast Investor Call Tuesday, May 14, 2024
View all News
Agenda
29
October
United Kingdom
Copthorne Tara Hotel, London, UK
International Dismounted Soldier, 29-30 October 2024, Copthorne Tara Hotel, London, UK
Navigating the Evolving Battlespace: Enhancing the Capabilities of the Dismounted Soldier The modern battlefield...
24
September
United Kingdom
Hilton London Syon Park, London, UK
Defence Transformation Conference, 24-26 September 2024, Hilton London Syon Park, London, UK
Returning for its 8th year, Defence Transformation 2024 will feature an updated format that will address all aspects of...
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
View All Events